Eisai's Fycompa approved in US with boxed warning, awaits DEA scheduling
This article was originally published in Scrip
Executive Summary
Eisai's novel antiepileptic drug Fycompa (perampanel) has been approved by the US FDA after a bumpy regulatory ride, for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in epilepsy patients aged 12 or older.
You may also be interested in...
J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration
Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every six months injection for schizophrenia, Spravato for suicidal ideation, and earlier programs in Alzheimer's disease.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.